Join to View Full Profile
35 Cambridgepark DrCambridge, MA 02140
Phone+1 617-665-7796
Dr. Berkenblit is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Harvard Medical SchoolClass of 1996
Certifications & Licensure
MA State Medical License 1998 - 2026
Clinical Trials
- Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia Start of enrollment: 2016 Mar 01
Publications & Presentations
PubMed
- 72 citationsMirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.Kathleen N Moore, Antoine Angelergues, Gottfried E Konecny, Yolanda García, Susana Banerjee
The New England Journal of Medicine. 2023-12-07 - 150 citationsPhase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.Kathleen N. Moore, Amit M. Oza, Nicoletta Colombo, Ana Oaknin, Giovanni Scambia
Annals of Oncology. 2021-06-01 - 192 citationsAntibody-Drug Conjugates for Cancer Treatment.John M. Lambert, Anna Berkenblit
Annual Review of Medicine. 2018-01-29
Press Mentions
The Pernicious CancerFebruary 10th, 2025- Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic CancerJune 20th, 2024
- ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid LeukemiaDecember 9th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
